Clinical Scorecard: RSV Prevention Tied to Lower Infant Acute Care Use
At a Glance
| Category | Detail |
|---|---|
| Condition | Respiratory Syncytial Virus (RSV) |
| Key Mechanisms | Use of nirsevimab and maternal RSV vaccination |
| Target Population | Infants aged 7 months or younger |
| Care Setting | Emergency departments and hospitals |
Key Highlights
- 43% relative decrease in RSV-associated hospitalizations and ED visits among infants aged 7 months or younger during the second year of nirsevimab use.
- Estimated effectiveness of nirsevimab is between 77% to 90%.
- Population-level impact observed with increased immunization coverage in the second season.
- Median age of RSV cases increased from 9 months to 12 months over the study period.
- Clesrovimab, a new monoclonal antibody, offers an alternative prevention strategy.
Guideline-Based Recommendations
Diagnosis
- Use International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes for RSV-related diagnoses.
Management
- Nirsevimab recommended for infants at increased risk for severe RSV disease.
Monitoring & Follow-up
- Track hospitalization and emergency department visit rates for RSV.
Risks
- Potential misclassification due to reliance on diagnosis codes rather than laboratory confirmation.
Patient & Prescribing Data
Infants born from October 2023 to March 2024, with 39% immunization coverage.
Clesrovimab approved in June 2025, providing a long-acting alternative.
Clinical Best Practices
- Evaluate the need for specific recommendations for Native Hawaiian or Other Pacific Islander children.
- Consider population-level impacts when assessing RSV prevention strategies.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
